Boehringer Ingelheim has received FDA approval for its drug Ofev as a first-line treatment for non-small cell lung cancer. The approval offers a new option for patients with metastatic NSCLC, combining Ofev with chemotherapy for better outcomes.
LTM has entered a seven-year, $100 million partnership with a leading European MedTech company specializing in hearing solutions, focusing on product development, digital support, and compliance management for hearing devices.
Mahajan Imaging & Labs reports an 85% rise in Calcium Scoring CT and 36% growth in advanced cardiac scans, highlighting early heart risk among young Indians and the need for preventive cardiology.
Novo Nordisk has signed a $2.1 billion deal with Vivtex to develop an oral obesity drug platform, aiming to turn injectable weight-loss treatments into easy-to-take pills and expand patient access worldwide.
Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection in India by March following patent expiry, aiming to offer a significantly lower-cost option for diabetes and weight-loss patients.
GSK plc will acquire Canada-based 35Pharma for $950 million, adding HS235, a phase I-ready drug candidate for pulmonary hypertension, to strengthen its growing cardiopulmonary pipeline.
Zydus Lifesciences is preparing a day-one launch of its semaglutide generic in India after patent expiry in March 2026. The drug will be sold as Semaglyn, Mashema, and Altreme with a reusable multi-dose pen.
.png "Lupin Secures FDA Approval for Brivaracetam Oral Solution")
Lupin Limited has announced FDA approval for its Brivaracetam Oral Solution 10 mg/mL, a bioequivalent of UCB’s Briviact, designed to treat partial-onset seizures in patients 1 month and older. The launch is now underway in the U.S.
Gilead Sciences is acquiring Arcellx in a deal valued at up to $7.8 billion, gaining full control of its CAR-T therapy candidate for multiple myeloma and strengthening its oncology pipeline.
Shilpa Medicare has signed a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America, strengthening its biologics portfolio and expanding its presence in emerging markets.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")